New COPD drug wins backing of US FDA panel advisers

The U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee (PADAC) on Feb. 24 voted 12 to 2 in favor of approving the New Drug Application (NDA) for Spain based Almirall’s aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of COPD, accoridng to Daewoong Pharmaceutical Co.

On Feb. 13, Daewoong signed with Almirall an agreement by which A...